Diabetes：GDP11可提高EPCs的血管生成功能，为糖尿病肢体缺血提供新的治疗方法

2018-07-24 MedSci MedSci原创

生长分化因子11（GDF11）可提高干细胞活性，使老年小鼠的多种器官功能年轻化，但GDF11在后肢缺血的糖尿病大鼠模型中的功能尚不明确。现有研究人员发现系统补充GDF11可恢复内皮祖细胞（EPCs）的血管生成功能，进而增加血管形成、提高后肢缺血的糖尿病大鼠的血流。与此相反，抗GDF11单克隆抗体治疗可导致血管生成受损，导致血流减少。在体外，用GDF11处理EPCs可缓解EPCs功能异常、减少其凋亡

生长分化因子11（GDF11）可提高干细胞活性，使老年小鼠的多种器官功能年轻化，但GDF11在后肢缺血的糖尿病大鼠模型中的功能尚不明确。

现有研究人员发现系统补充GDF11可恢复内皮祖细胞（EPCs）的血管生成功能，进而增加血管形成、提高后肢缺血的糖尿病大鼠的血流。与此相反，抗GDF11单克隆抗体治疗可导致血管生成受损，导致血流减少。

在体外，用GDF11处理EPCs可缓解EPCs功能异常、减少其凋亡。在机制上，GDF11介导的正性作用可归因于转化生长因子-β/Smad2/3和蛋白激酶B/低氧诱导因子1α（AKT/HIF1α）信号通路的激活。

本研究结果提示GDF11充足可增强EPCs耐受糖尿病诱导的损伤，提高血管生成，进而增加血流。GDF11或可为糖尿病肢体缺血提供新的治疗方法。

原始出处：

Jiajia Zhang，et al. GDF11 Improves Angiogenic Function of EPCs in Diabetic Limb Ischemia. Diabetes 2018 Jul； db171583. https：//doi.org/10.2337/db17-1583

本文系梅斯医学（MedSci）原创编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2018-12-19 木头人513

#Diabetes#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2019-03-08 ms5439512287675881

#BET#

27 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2018-10-19 freve

#GDP#

36 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2019-06-01 ms9608593228839890

#DIA#

20 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2018-10-21 Tamikia

#PCS#

21 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2018-07-26 showtest

#治疗方法#

19 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2018-07-24 misszhang

谢谢MedSci提供最新的资讯

47 0
[GetPortalCommentsPageByObjectIdResponse(id=1902098, encodeId=1fbd19020986a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Dec 19 10:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760755, encodeId=30751e6075565, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 08 05:20:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968144, encodeId=c54819681448b, content=<a href='/topic/show?id=38c6e9084a' target=_blank style='color:#2F92EE;'>#GDP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7908, encryptionId=38c6e9084a, topicName=GDP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Fri Oct 19 05:20:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638700, encodeId=81341638e008c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 01 00:20:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685608, encodeId=145616856089e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Oct 21 17:20:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399255, encodeId=f92a1399255b7, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Thu Jul 26 02:20:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041729, encodeId=32ed1041e2965, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 24 14:20:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333848, encodeId=9ed6333848e0, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Tue Jul 24 11:55:43 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
2018-07-24 lietome2

好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！

40 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

糖尿病

Diabetes：GDP11可提高EPCs的血管生成功能，为糖尿病肢体缺血提供新的治疗方法

相关资讯

科室

工具

服务